In 2024, California had the highest number of liver transplants performed among all U.S. states. That year, there were around 1,243 liver transplants performed in California. The state with the second-highest number of liver transplants was Texas. Liver transplants are the second most common transplant in the United States, behind kidney transplants. Liver transplants in the United States In 2023, there were just over 10,660 liver transplants carried out in the United States. Most liver transplants in the U.S. are among adults aged 50 to 64 years, with this age group accounting for around 43 percent of all liver transplants. The current need for liver transplants exceeds availability, with over nine thousand people in the United States waiting to receive a liver transplant. Liver transplantation is a treatment option for those suffering from end-stage chronic liver disease, in which the liver is damaged beyond repair. Liver disease End-stage chronic liver disease, or liver failure, has various causes including cirrhosis, hepatitis B and C, and liver cancer. Around half of all deaths in the United States caused by liver cirrhosis are related to alcohol use. Liver cirrhosis is scarring of the liver because of long-term damage. The death rate due to alcohol-related cirrhosis in the United States has increased over the past couple decades. Men are much more likely to die from liver cirrhosis than women.

According to the data, in 2024 there were a total of around ****** liver transplants in the United States, of which ***** recipients were ***** years of age. This statistic depicts the number of liver transplant recipients in the U.S. in 2024, by age.

The number of liver transplants worldwide shows extreme regional variation. As of 2023, the Americas, Europe, and Western Pacific had the largest number of liver transplants. The Americas, with the largest number, had almost 15 thousand liver transplants in 2023. Organ donors Organs can be donated in two ways, upon a person’s death or from a living person in some circumstances. Among select OECD countries in 2022, Spain and the United States had the highest rates of deceased organ donors, followed by Portugal. In the United States, the majority of organ donors are deceased, with deceased donors accounting for around 70 percent of all organ donors in 2023. That year, there were a total of 23,297 organ donors in the United States. Kidney transplants worldwide Among all types of transplants performed globally, kidney transplants represent a majority of all organ transplants. Much like the data indicated for liver transplants, kidney transplants also show distinct regional differences. Among all regions, the Americas and Europe had the largest number of kidney transplants in 2023.

According to the data, the number of living liver donors increased from * in 1988 to *** in 2024. This statistic depicts the number of liver organ donors in the U.S. from 1988 to 2024, by donor type.

In 2024, there were ****** organ transplants in the United States. This was the highest number ever, with the second-highest number of transplants reported in 2023. In the United States, the most commonly transplanted organs are the kidneys, liver, and heart. Who donates organs in the United States? In 2024, there were just over ****** organ donors in the United States. Men accounted for around ** percent of organ donors that year. Some organs, such as a kidney, can be donated while the donor is alive, but most donations occur after the donor has deceased. For this reason, it is no surprise that most organ donors in the United States are older adults. In 2024, the highest number of organ donors were in the age group 50–64 years. Although the number of organ donors in the U.S. has increased gradually over the past few decades, those requiring an organ transplantation still far outnumber donors, with thousands currently on waiting lists to receive an organ transplantation that may save their life. Waiting lists for transplants In the United States, there were ******* candidates waiting for an organ transplantation as of May 2025. Around ** percent of these candidates were waiting for a kidney transplantation, while *****percent needed a liver transplant. Older adults are more likely to need an organ transplant than younger people, with those aged 50 to 64 years accounting for the highest number of candidates on organ donation waiting lists.

The demand for organ transplants in the United States continues to outpace supply, with over 105,000 individuals awaiting life-saving procedures as of May 2025. Kidneys remain the most sought-after organ, accounting for nearly 87 percent of all transplant candidates. This significant need underscores the ongoing challenges in organ donation and allocation across the country. Trends in transplantation rates While the waiting list for organs remains long, there have been notable improvements in transplantation rates for certain organs. For instance, the rate of lung transplants per million inhabitants in the United States nearly doubled from 4.9 in 2008 to 9.1 in 2023. This increase reflects advancements in medical technology and improved organ procurement processes. Liver transplants Liver transplants are the second most common type after kidney transplants. In 2024, individuals aged 50-64 received the highest number of liver transplants, with 4,949 procedures performed for this age group. California led the nation in liver transplants performed in 2024, followed by Texas, highlighting regional variations in organ availability and medical capabilities.

The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) was a consortium of 9 U.S. liver transplant centers performing adult-to-adult living donor liver transplant (AALDLT) with the primary goal of examining outcomes of AALDLT versus deceased donor liver transplant (DDLT). AALDLT is a relatively new procedure increasingly used at major transplantation centers. Relatively small numbers of cases are performed at any one center and approaches to the patient and donor are too diverse across centers to provide reliable and generalizable information on donor and recipient outcomes from individual centers. Therefore, the consortium was organized to accrue and follow sufficient numbers of patients being considered for and undergoing AALDLT to provide generalizable results from adequately powered studies.

The Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL) consisted of both retrospective and prospective studies of AALDLT. Legacy data from the A2ALL retrospective cohort is housed in the NIDDK Data Repository. The A2ALL retrospective cohort comprised 819 adult patients, each with a potential living donor, evaluated between January 1, 1998 and February 28, 2003. The retrospective study was designed to gain initial insights into outcomes associated with liver transplant procedures, with data drawn from existing medical records and patient materials. It was hypothesized that pursuit of a living liver allograft leads to decreased pre-transplant morbidity and mortality and better long term outcomes for patients starting from the point at which listed patients have a potential donor evaluated (at least a history and physical examination). The study analyzed numerous variables to determine the factors influencing allograft survival in recipients.

The A2ALL study showed evidence that AALDLT is a viable option for liver replacement with outcomes that improve with center experience. Donor characteristics associated with survival included younger age and cold ischemia time of the right lobe graft.

MRI and CT Scan images from subjects enrolled in A2ALL are not included in the data package, but are available upon request.

In 2024, nearly ****** liver transplants were performed in the United States. While over ***** kidney transplants took place, there were approximately ***** heart transplants that year.

The size of the U.S. Transplantation Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 8.5 % during the forecast period. U.S. transplantation refers to a medical procedure whereby organs, tissues, or cells from one human being (the donor) are transferred to another (the recipient) as a treatment measure for any of the life-threatening conditions affecting the latter. The majority of transplants conducted within the U.S. fall into the category of kidney, liver, heart, lung, and pancreas transplants. Since the advent of transplant services, medical technology, surgery techniques, and immunosuppressive therapies have improved over time greatly. The U.S. transplant system is managed through agencies such as the United Network for Organ Sharing, which coordinates organ allocation. However, the gap between the number of individuals in need of transplants and the number of organ donors is still very large, resulting in long waiting periods for many patients. Continuous efforts are being made to enhance awareness about organ donation, improve preservation methods, and explore alternatives like bioengineered organs. U.S. transplantation continues to be an important field in medical research, which can also offer hope for patients who experience end-stage organ failure. Recent developments include: In May 2022, Medtronic plc partnered with DaVita, Inc. to form a novel, independent kidney care-focused medical device company NewCo to enhance the overall outcomes and patient treatment. , In February 2022, Veloxis Pharmaceuticals, Inc. announced that VEL-101 immunosuppressive agent received fast track designation by the U.S FDA. VEL-101 is an investigational novel maintenance immunosuppressive agent purposed for prophylaxis of renal allograft rejection for kidney transplant in patients. .

The only national patient waiting list and an online database system, called UNet, that links all of the professionals involved in the donation and transplantation system for the collection, storage, analysis, and publication of all OPTN data pertaining to the patient waiting list, organ matching, and transplants. The system contains data regarding every organ donation and transplant event occurring in the U.S. since October 1, 1987. UNet is a fail-safe, 24/7, secure Internet-based transplant information database created to enable the nation''''s organ transplant institutions to: * register patients for transplants * match donated organs to waiting patients * manage the time-sensitive, life-critical data of all patients, before and after their transplants Data reports are available by type: National Data, Regional Data, State Data, Center Data, Build Advanced Report, and Annual Report Data. UNet is being used right now by all of the nation''''s organ transplant programs, organ procurement organizations, and histocompatibility (tissue typing) laboratories working cooperatively to efficiently share a limited number of donated organs among thousands of patients.

This statistic shows the number of selected organ transplantations performed in the United States, comparing the years 2008 and 2023. In 2008, the number of heart transplants in the U.S. stood at 2,163. This number had increased to 4,599 in 2023. Organ transplantations in the United States The number of liver transplants in the United States reached 10,660 cases in 2023. In this year, there were 3,080 lung transplants. Organ transplants are one of the only methods for treating organ failure. Survival rates are fairly high after the first year, at 90.4 percent for a heart transplant patient, however, survival rates drop after longer follow-up periods, at 58.5 percent after a 10 year follow up period for heart transplant patients. There are several different types of transplants such as an allograft and a domino transplant. An allograft is characterized by transplanting an organ or tissue to a different person, the rejection of the organ will likely occur where the recipient’s immune system will attempt to destroy the foreign organ. Risk of rejection must be carefully measured and calculated prior to the procedure.

As per the latest report published by the cognitive Market Research, The Transplant Diagnostic Market was valued at USD 4.52 Billion in 2022 and is projected to reach USD 7.43 Billion in 2030, registering a CAGR of 7.5% in the forecast period of 2023-2030. Factors Affecting Transplant Diagnostics Market Growth

Increasing Pervasiveness of Chronic Diseases

The increasing incidence of chronic diseases worldwide has greatly contributed to the growing demand for organ transplantation. With aging populations worldwide, the incidence of chronic diseases like diabetes, hypertension, cardiovascular disease, and most notably chronic kidney disease (CKD), is rapidly increasing. CKD has risen to become one of the top causes of kidney failure, pushing it up the ranks as a top driver for kidney transplant procedures. As life expectancy rises, the rates of chronic conditions also rise, especially in the elderly who are more prone to long-term health complications. For instance, more than 1 in 7 US adults about 35.5 million people, or 14% are estimated to have CKD. (Source - https://www.cdc.gov/kidney-disease/php/data-research/index.html ) Alongside this, advances in medical science are opening doors to newer treatments like stem cell therapy and personalized medicine. These new areas are gaining momentum because of their ability to deliver targeted, effective, and patient-specific treatments. With these advancements, the significance of precise and thorough pre-procedure diagnostics has increased significantly. Early diagnosis and assessment are key to enhancing transplant success rates, reducing complications, and tailoring treatment plans according to individual patient profiles. Consequently, the need for pre-procedure diagnostic technologies and equipment is increasing rapidly. This trend is part of a larger movement toward proactive and precision medicine, opening up opportunities for innovation in diagnostic and therapeutic support systems in organ transplantation.

The increasing number of transplant procedures

The increasing number of numerous new advanced technologies, screening tests, genomic profiling, and cross-matching is making the transplant a relevant way of giving rebirth to an individual. The growing number of transplant processes across major countries is associated with the increasing CAGR in the transplant market. Diseases such as liver cirrhosis, Tuberculosis, and end-stage renal diseases are prevalent among ancient individuals and the individual must go through transplant surgery.

Restraining Factors of the Transplant Diagnostic Market

High cost of NGS and PCR-based diagnostic evaluation

Transplant diagnostic processes are conducted through particular molecular diagnosis dais that contains numerous advanced technologies for processing Histocompatibility tests, genomic profiling, and Blood profiling. All these technologies are combined with the conventional NGS/PCR instruments and therefore, the cost of these advanced products is high. The huge cost of instruments is restraining the growth of the market.

The increasing gap between organ donors and organ transplantation 

The enormous gap between organ donation and the requirement for organ transplantation is reducing the growth of the transplant diagnosis market. The number of organ donors is falling smaller than the number of people requiring organ transplantation. This creates an enormous loss between the supply and requirement of organ donors, with the number of people on the pending list for organ transplants increasing by the year.

Opportunities in the Transplant diagnostics market:

Vital drive by the key players

Increasing global demand for transplant diagnostics is posing important opportunities for strategic business expansion in the health care industry. With increasing worldwide demand for organ donors, the demand for good quality transplant diagnostic kits is simultaneously increasing. The kits are vital for determining donor-recipient compatibility, avoiding organ rejection, and enhancing transplant success rates. Growing pressure to address this need has urged main market participants to adopt aggressive approaches with a focus on improving their market foothold and operation ability. For instance, as of 2022, 170 million people in the U.S. have registered as donors. (Source - https://www.organdonor.gov/learn/organ-donation-statistics ) ...

The age group with the largest number of individuals on the transplant waiting list in the U.S. as of May 7, 2025 was those aged 50-64 years. This age group had 44,025 patients waiting to receive transplants at that time. There is an extensive need for organ donations in the United States. Organ donations In the U.S. deceased donors can donate kidneys, liver, lungs, heart, pancreas and intestines. Living donors can donate one kidney, one lung or a portion of the liver, pancreas or intestine. Organs are donated mostly from middle-aged U.S. adults. Among all age groups, those aged 50 to 64 years had the highest number of organ donors in 2024. Waiting lists The number of organ donors in the U.S. has increased dramatically since 1988. Despite such a dramatic increase in the number of donors, there is still a great need among U.S. patients. As of May 2025, the organs with the most patients waiting for transplants in the U.S. were kidneys and livers. Over 91 thousand patients required a kidney at that time.

To assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC). A cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a “watch and wait” state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature. At five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained. TARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators. The Barcelona Clinic Liver Cancer guideline recommends the use of transarterial radioembolization (TARE), conventional (cTACE), or drug-eluting bead transarterial chemoembolization (DEE-TACE) for treating hepatocellular carcinoma (HCC). This study evaluated the cost-effectiveness of TARE versus two alternative embolization treatments (cTACE and DEE-TACE) in treating patients with unresectable early- to intermediate-stage HCC. A cohort-based Markov model was developed to analyze the costs and benefits of these treatments from a US healthcare perspective within a 5-year time horizon. A 20-year time horizon was assessed as a scenario. In the model, patients were assigned to receive TARE, cTACE, or DEE-TACE and remained in the “watch and wait” stage for tumor downstaging. Data used in the model was taken from previous studies and in consultation with clinical experts. The benefits of the treatments were measured by considering the impact on the patient’s quality of life. The costs associated with the treatments were obtained from various sources, including reports, publicly available databases, and published literature. The findings show that TARE is not only cost-saving compared to cTACE but also results in a higher number of quality-adjusted life years (QALYs) per person. While TARE was more expensive than DEE-TACE, it produced more QALYs, further indicating more favorable patient outcomes and overall treatment effectiveness. These findings could potentially impact resource allocation and decision-making for the treatment of HCC.

Snapshot img

Ursodeoxycholic Acid Market Size 2025-2029

The ursodeoxycholic acid market size is forecast to increase by USD 550.4 million, at a CAGR of 12.9% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing number of liver transplants and the rising demand for combination therapies. The escalating need for effective liver disease treatments, particularly in light of the growing number of liver transplants, is fueling market expansion. Furthermore, the trend towards combination therapies, which often include Ursodeoxycholic Acid, is adding to the market's momentum. However, the market faces challenges as well. The expiry of patents on branded Ursodeoxycholic Acid drugs is leading to increased competition from manufacturers of generics. This price pressure may impact market growth and profitability for some players. Companies seeking to capitalize on market opportunities should focus on developing innovative combinations and differentiated offerings, while also addressing the challenges posed by generic competition through strategic pricing and marketing efforts.

What will be the Size of the Ursodeoxycholic Acid Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by the expanding applications of this versatile bile acid in various sectors of liver disease management. With a growing emphasis on fibrosis reduction and liver cell protection, ursodeoxycholic acid has emerged as a key player in the treatment of primary biliary cirrhosis and fatty liver disease. Bile acid composition plays a crucial role in the therapeutic efficacy of ursodeoxycholic acid. Its choleretic effect promotes hepatic bile flow, while its cytoprotective effects protect liver cells from damage. In fact, a study showed that ursodeoxycholic acid led to a 30% reduction in fibrosis progression in primary biliary cirrhosis patients over a five-year period.

Moreover, ursodeoxycholic acid's role extends beyond liver disease management. It is also used to manage cholestasis, enhance gallbladder function, and promote intestinal absorption. The ongoing research into bile acid transporters, receptors, and metabolism continues to unveil new potential applications for this bile acid. The market is poised for significant growth, with industry analysts projecting a steady expansion of 5% annually over the next decade. The development of drug delivery systems, bile salt therapy, and conjugated bile acid formulations further enhances the therapeutic potential of ursodeoxycholic acid. In addition to its well-established uses, recent research has explored the potential of ursodeoxycholic acid in inflammation reduction and hepatic injury prevention.

Furthermore, its role in cholesterol gallstones treatment and hepatic enzyme induction adds to its versatility. The intestinal microbiota plays a role in bile acid synthesis and conjugation, and the ongoing research into the interplay between bile acids and the microbiome offers exciting possibilities for future applications. The continuous unfolding of market activities and evolving patterns underscores the dynamic nature of the market.

How is this Ursodeoxycholic Acid Industry segmented?

The ursodeoxycholic acid industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

Synthetic Extraction

Application

Pharmacy products Health products

Distribution Channel

Hospital pharmacies Retail pharmacies Online pharmacies

Geography

North America

US Canada

Europe

France Germany Italy UK

APAC

China India Japan

South America

Brazil

Rest of World (ROW)

By Type Insights

The synthetic segment is estimated to witness significant growth during the forecast period.

Synthetic ursodeoxycholic acid, a crucial component in pharmaceutical formulations, is produced through controlled chemical processes using precursor compounds. Its consistent quality is a significant advantage, ensuring highest efficacy in various applications. In liver disease management, ursodeoxycholic acid plays a pivotal role, reducing fibrosis in primary biliary cirrhosis and aiding in gallbladder function and hepatic bile flow. Its choleretic effect stimulates bile acid secretion, while its cytoprotective properties shield liver cells from damage. In the context of fatty liver disease, ursodeoxycholic acid has shown promise in cholesterol gallstones treatment and inflammation reduction. Bile acid transporters play a role in its absorption, while conjugated bile acids facilitate drug delivery systems.

The metabolism of bile acids involves bile acid receptors and homeostasis, which ursodeoxycholic

According to Cognitive Market Research, the global Sirolimus market size will be USD 291.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 5.20% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 107.97 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.0% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 84.62 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 70.03 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 11.09 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 11.67 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 6.42 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2033.
Online pharmacies are expected to experience the fastest CAGR during the forecast period

Market Dynamics of Sirolimus Market

Key Drivers for Sirolimus Market

Increasing organ transplantation Boost Market Growth

Globally, the number of organ transplant surgeries has increased in recent years due to factors such as improved surgical techniques, increased awareness of organ donation, and advancements in post-transplant care. Sirolimus is a type of immunosuppressant that is commonly used to prevent rejection in organ transplants. With more transplants, there is a greater demand for immunosuppressive drugs like Sirolimus. The Global Observatory on Donation and Transplantation (GODT) predicts approximately 157,494 solid organ transplants in 2022. This represents a 9.1% increase over 2021, but it still falls short of meeting less than 10% of global demand. The kidney is the most commonly transplanted organ, followed by the liver and the heart. In 2023, 46,636 organ transplants were performed, an increase of 8.7% over 2022 and 12.7% over 2021. This year saw a new high in organ transplants. By January 2023, more than 107,000 people in the United States were waiting for organ transplants. Furthermore, after COVID-19, India resumed organ transplant efforts in 2022, with over 15,000 transplants completed. According to the National Organ and Tissue Transplant Organization (NOTTO), there were 12,791 living donor transplants, the majority of which took place in private facilities. As a result, the rise in organ transplant procedures directly impacts the Sirolimus market trend

https://unos.org/news/2022-organ-transplants-again-set-annual-records/

Rise in Chronic Diseases Boost Market Growth

The increasing prevalence of chronic diseases such as diabetes, hypertension, and autoimmune conditions raises the demand for immunosuppressants like sirolimus. These chronic diseases frequently necessitate transplants or long-term treatment, which frequently includes sirolimus therapy. Chronic diseases become more common as the world's population ages and lifestyles change, necessitating the development of effective treatment options. Pharmaceutical companies are focusing on developing novel sirolimus formulations to drive growth in the API market. Furthermore, the rising prevalence of chronic diseases heightens the need for dependable immunosuppressive therapies, which positively influences Sirolimus Market dynamics

Restraint Factor for the Sirolimus Market

High cost of the treatment Limit Market Growth

Sirolimus is a specialised drug that suppresses the immune system in organ transplant recipients and people with certain medical conditions. When compared to more common prescriptions, speciality drugs are often more expensive. Patients and healthcare systems may be concerned about the cost of Sirolimus. The cost of speciality drugs such as Sirolimus may put a strain on the financial resources of healthcare providers and payers in areas where healthcare budgets are tight. According to NCBI, the average cost of a 1g dose of immunosuppressants for a 70kg patient is USD 10,500, while a 2g...

Snapshot img

The primary sclerosing cholangitis treatment market size has the potential to grow by USD 37.50 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.

This report provides a detailed analysis of the market by product (UDCA and other therapeutics) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Dr. Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Lannett Co. Inc., Mylan NV, Strides Pharma Science Ltd., and Teva Pharmaceutical Industries Ltd.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Primary Sclerosing Cholangitis Treatment Market

Request a FREE sample now!

Market Competitive Analysis

The primary sclerosing cholangitis treatment market is fragmented. AbbVie Inc., Amneal Pharmaceuticals Inc., and Apotex Inc. are some of the major market participants. Factors such as a rise in the number of liver transplants and UDCA treatment, increasing incidence of diseases associated with primary sclerosing cholangitis, and growth in the availability of treatment will offer immense growth opportunities. However, poor understanding of primary sclerosing cholangitis pathogenesis, late detection of primary sclerosing cholangitis, and overlap syndromes creating problems during diagnosis may impede market growth. To make the most of the opportunities, vendors should focus on growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market position, this primary sclerosing cholangitis treatment market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this primary sclerosing cholangitis treatment market analysis report provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading companies, including:

AbbVie Inc.
Amneal Pharmaceuticals Inc.
Apotex Inc.
Dr. Reddys Laboratories Ltd.
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson
Lannett Co. Inc.
Mylan NV
Strides Pharma Science Ltd.
Teva Pharmaceutical Industries Ltd.

Primary Sclerosing Cholangitis Treatment Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. North America will offer several growth opportunities to market vendors during the forecast period.

47% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for primary sclerosing cholangitis treatment in North America. This report provides an accurate prediction of the contribution of all segments to the growth of the primary sclerosing cholangitis treatment market size.

Primary Sclerosing Cholangitis Treatment Market: Key Highlights of the Report for 2020-2024

CAGR of the market during the forecast period 2020-2024
Detailed information on factors that will drive primary sclerosing cholangitis treatment market growth during the next five years
Precise estimation of the primary sclerosing cholangitis treatment market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the primary sclerosing cholangitis treatment industry across Asia, Europe, North America, and ROW
A thorough analysis of the market’s competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of primary sclerosing cholangitis treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

    Primary Sclerosing Cholangitis Treatment Market Scope




    Report Coverage


    Details




    Page number


    120




    Base year


    2019




    Forecast period


    2020-2024




    Growth momentum & CAGR


    Accelerate at a CAGR of 4%




    Market growth 2020-2024


    $ 37.50 million




    Market structure


    Fragmented




    YoY growth (%)


    3.43




    Regional analysis


    North America, Eur